Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

The Promise of Immunotherapy for Cancer Treatment

Advertisements

Figure 5. Treatment of the checkpoint inhibitor related toxicity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Multiscale modelling in oncology

Figure 1 Radiation-induced effects on tumour cells

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 2 Signalling pathways and physiological domains that are

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Chimeric antigen receptor (CAR) structures

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 CAR-T-cell design

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 6 Combination therapy for HCC

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 3 Structure of different types of T-cell-engaging antibodies

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The role of CTLA4 and PD1 in T cell activation

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 2 Site of action of checkpoint inhibitors and agonists being

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 1 Mechanisms of action of immunotherapy modalities

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Figure 4 Molecular signalling and immunological

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.58 Figure 4 Management of immune-related adverse events excluding skin and endocrine toxicities Figure 4 | Management of immune-related adverse events excluding skin and endocrine toxicities. General guidelines for the management of immune-related adverse events attributed to checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death 1 (PD-1). Boutros, C. et al. (2016) Safety profiles of anti-CTLA‑4 and anti‑PD‑1 antibodies alone and in combination Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.58